Company / Accounts Receivable
Co-Diagnostics, Inc. Accounts Receivable History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$190.4K
FY2025
5-year range
$132.6K / $20.8M
FY2021-FY2025
Trend
+43.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable returned to growth in FY2025 after 3 years of decline, reaching $190,375.
Based on SEC 10-K filings.
$190,375 in FY2025 with a 5-year CAGR of -56.4%.
Declined from $303,926 to $190,375 over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -61.9%
- 5-Year CAGR
- -56.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -56.4%, indicating a declining trend.
- In FY2025, accounts receivable increased 43.6% year-over-year.
- Peak accounts receivable was recorded in FY2021.
- Lowest accounts receivable in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.63 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $190.4K | +43.6% |
| FY2024 | $132.6K | -56.4% |
| FY2023 | $303.9K | -91.2% |
| FY2022 | $3.5M | -83.4% |
| FY2021 | $20.8M | +71.7% |
| FY2020 | $12.1M | +9137.8% |
| FY2019 | $131.4K | +879.0% |
| FY2018 | $13.4K | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026